Physician profile
Shiu-Chung Au
NPI 1841424272
$303,693.58
in general payments reported to CMS, 2019-2025
19 companies · $125K in 2025
The $125K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $147 · 2021: $489 · 2022: $18K · 2023: $65K · 2024: $94K · 2025: $125K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $238K · Travel and Lodging: $18K · Consulting Fee: $18K · Food and Beverage: $9,886 · Education: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $238,218.00 |
| Travel and Lodging | $18,103.18 |
| Consulting Fee | $17,762.50 |
| Food and Beverage | $9,886.15 |
| Education | $340.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $129,712.66 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $123,844.45 | 2020-2025 | Tremfya, Simponi Aria, Stelara |
| Kowa Pharmaceuticals America, INC. | $25,507.40 | 2025 | Zoryve |
| Arcutis Biotherapeutics, INC. | $20,729.21 | 2024-2025 | Zoryve |
| Abbvie INC. | $888.87 | 2020-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $704.92 | 2024-2025 | Bimzelx |
| Amgen INC. | $463.52 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $365.82 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $350.78 | 2020-2025 | Absorica Ld, Winlevi |
| Incyte Corporation | $236.31 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $204.00 | 2024-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $164.14 | 2024-2025 | Sotyktu |
| Leo Pharma INC. | $157.02 | 2020-2025 | Adbry |
| Genzyme Corporation | $130.96 | 2025 | |
| Pfizer INC. | $86.23 | 2021-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $47.36 | 2025 | Hadlima |
| Botanix Sb INC | $43.36 | 2025 | Sofdra |
| Regeneron Healthcare Solutions, INC. | $34.14 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.43 | 2024 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiu-Chung Au listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.